Abstract
Thus, we conclude that 2b targets tumors, inhibits tumor growth and prevents lung metastasis.
Introduction
Platinum-based chemotherapies like cisplatin remain standard treatments but are often limited by severe systemic toxicity and acquired drug resistance. Ruthenium complexes have emerged as a compelling alternative, offering unique biochemical profiles and lower toxicity. However, a persistent challenge in the field is that most ruthenium candidates, such as NAMI-A, effectively inhibit metastasis but fail to suppress the growth of the primary tumor. To address this, researchers developed 2b, a novel ruthenium(IV) nanodrug designed for dual-targeting of both primary and metastatic cancer sites.
Design and Characterization of Nanodrug 2b
The researchers synthesized 2b by coordinating a carboline acid derivative with a ruthenium(IV) center. Molecular dynamics simulations predicted that these molecules would self-assemble into stable nanoparticles. Experimental validation using Transmission Electron Microscopy (TEM) and Scanning Electron Microscopy (SEM) confirmed the formation of spherical nanoparticles with an average diameter of approximately 50 nm.
The nanodrug employs a two-pronged targeting strategy. First, it utilizes the Enhanced Permeability and Retention (EPR) effect to passively accumulate in the leaky vasculature of tumors. Second, it actively targets cancer cells by binding to Human Transferrin (hTF). Since cancer cells overexpress transferrin receptors (TFR) significantly more than normal cells, 2b effectively "hitches a ride" into the tumor microenvironment.
Biological Mechanism and In Vitro Efficacy
In vitro assays demonstrated that 2b possesses potent cytotoxicity against various lung cancer cell lines, including A549 and paclitaxel-resistant A549-TAX. The drug induces cell cycle arrest at the G2/M phase. Mechanistically, Western blot analysis revealed that 2b triggers DNA damage and inhibits the PARP/ATM repair pathway, leading to programmed cell death (apoptosis).
The study also highlighted the drug's selectivity; 2b showed a significantly higher killing effect on lung cancer cells compared to normal human liver cells (L02), suggesting a favorable therapeutic window.
In Vivo Performance and Safety
Testing in Lewis lung carcinoma (LLC) mouse models confirmed the drug's dual efficacy. At a dose of 5.0 mg/kg, 2b significantly reduced primary tumor volume and weight while simultaneously suppressing lung metastasis. Biodistribution studies using ICP-MS showed that ruthenium preferentially accumulated in the tumor, accounting for 33.4% of the total detected amount.
Importantly, 2b exhibited a superior safety profile compared to traditional platinum drugs. Treated mice did not experience significant weight loss, and histological examinations showed no damage to major organs like the liver and kidneys.
Conclusion
The development of 2b represents a significant step forward in ruthenium-based oncology. By combining the anti-metastatic properties of ruthenium with the primary tumor-inhibiting potential of carboline derivatives in a nanoparticle format, the researchers have created a potent "dual-targeting" system. While some discrepancies in PDL1 expression between in vitro and in vivo models remain to be explored, 2b stands as a promising candidate for further clinical development.
Summary updated